期刊文献+

肺癌与肺部感染患者自身抗体谱的特点比较 被引量:1

Autoantibody Profile Comparison in Patients with Lung Cancer or Pulmonary Infection Disease
原文传递
导出
摘要 目的探讨肺癌、肺部感染患者血清抗核抗体(ANA)谱、类风湿因子(RF)的表现特点。方法采用免疫印迹法检测抗核抗体谱,免疫散射比浊法检测类风湿因子,对照分析90例肺癌患者(均经病理组织学或细胞学检查确诊)、100例肺部感染患者及36例健康人血清抗核抗体谱、类风湿因子的表现特点。结果肺癌患者ANA谱阳性率显著高于健康人群,60岁以上老年肺癌患者ANA谱阳性率显著高于同年龄段健康人群及肺部感染患者,同时,60岁以上老年肺癌患者ANA谱阳性率显著高于60岁以下肺癌患者。肺部感染患者ANA谱阳性率在各年龄组间无明显差异,虽然数据表明随年龄增大阳性率增高,但未取得统计学数据支持。RF阳性率各年龄段无明显差异,肺癌患者与肺部感染患者及健康人群相比,亦无明显差异。结论肺癌与抗核抗体谱有关,肺部感染无明显相关。 Objective To investigate the features of auto-antibody( include Antinuclear antibodies and rheumatoid factor) in the lung cancer patients and pulmonary infection disease patients. Methods Western blotting was used to identify the antinuclear antibodies(ANAs) and immun0turibidimetric assay were used to detect rheumatoid factor(RF). The features of 90 cases of lung cancer (diagnosed by pathology or cytology), 100 cases of pulmonary infection disease and 36 cases of health people were compared. Results There was a high positive rate of ANAs in lung cancer group as compared with pulmonary infection disease group and healthy people group, and the significant difference of high positive rate of ANAs presented frequently in people older than 60 years. There was no significant difference of RF among lung cancer and pulmonary infection disease and health people or different age group. Conclusion Lung cancer is positive correlated with ANAs. Pulmonary infection disease was no significant correlation.
出处 《中华全科医学》 2011年第9期1384-1386,共3页 Chinese Journal of General Practice
关键词 肺癌 肺部感染 ANA谱 类风湿因子 病例对照研究 Lung cancer Pulmonary infection Antinuclear antibodies Rheumatoid factor Case-control study
  • 相关文献

参考文献11

  • 1方立萍,吴紫权,乔京京,赵金波.吉西他滨单药治疗老年晚期非小细胞肺癌的临床观察[J].中华全科医学,2010,8(5):562-562. 被引量:8
  • 2沈璐琳,韩晓辉,郑秀娟,吴厚生.用SP2/0瘤细胞核或DNA免疫同系小鼠诱导抗核抗体的产生[J].上海免疫学杂志,2001,21(4):219-220. 被引量:10
  • 3Abu-5hakra M, Buskila D, Ehrenteld M, et al. Cancer and autoimmuni- ty;autoimmune and rheumatic features in patients with malignancies [ J ]. Ann Rheum Dis ,2001,60:433-441.
  • 4Engels EA. Inflammation in the development of lung cancer:epidemio- logical evidence [ J 1. Expert Rev Anticaneer Ther, 2008,8 (4) : 605- 615.
  • 5Soyseth V, Benth JS, Stavem K. The association between hospitalisation for pneumonia and the diagnosis of lung cancer [ J ]. Lung Cancer, 2007,57 ( 2 ) : 152 - 158.
  • 6陆再英,钟南山,古洁若,等.类风湿关节炎[M]//陆再英,钟南山.内科学.7版.北京:人民卫生出版社,2008:848.855.
  • 7Imran A, Neelam F,Tariq M. Incidence of circulating antinuclear anti- bodies in cancer patients [ J ]. Indian J Med Sei, 2003,57 ( 3 ) : 113- 116.
  • 8Peng YC, Hsieh SC, Yang DY, et al. Expression and clinical signifi- cance of antinuclear antibody in hepatitis C virus infection [ J]. J Clin Gastroenterol, 2001,33 ( 5 ) : 402 406.
  • 9夏晴,仲人前.肿瘤与自身免疫[J].国外医学(肿瘤学分册),2000,27(4):213-215. 被引量:13
  • 10Win T, Groves AM, Phillips GD. Antinuclear antibody positive pleural effusion in a patient with tuberculosis [ J ]. Respirology,2003,8 (3) : 396-397.

二级参考文献50

共引文献28

同被引文献14

  • 1董强刚,韩宝惠,黄进肃,杨立民,黄建,赵春英,卢丽琴.176例非小细胞肺癌的EGFR基因突变分析[J].中华肿瘤杂志,2006,28(9):686-690. 被引量:53
  • 2Fukuoka M, Wu Y L, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase 1II, randomized, open-label, first-line study of gefitinib versus carboplatin/paclftaxel in clinically selected patients with ad- vanced non-small-cell lung cancer in Asia (IPASS) [J ]. J Clin Oncol, 2011, 29(21): 2866,.
  • 3Kim Y T, Kim T Y, Lee D S, et al. Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung[J]. Lung Cancer, 2008, 59( 1 ) 111.
  • 4Li C, Fang R, Sun Y, et al. Spectrum of oncogenic driver mutations in lung adenocarcinornas from East Asian never smokers[J]. PLoS One, 2011, 6(11): e28204.
  • 5Paez J G, Janne P A, Lee J C, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy[J]. Science, 2004, 304(5676): 1497.
  • 6Lynch T J, Bell D W, Sordella R, et al. Activating muta- tions in the epidermal growth factor receptor underlying re- sponsiveness of non-small-cell lung cancer to gefitinib [ J ]. N Engl J Med, 2004, 350(21): 2129.
  • 7Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib [J ]. Proc Natl Acad Sci USA, 2004, 101 ( 36 ) : 13306.
  • 8Mulloy R, Fen'and A, Kim Y, et al. Anderson KS and Set- tleman J : Epidermal growth factor receptor mutants from hu- man lung cancers exhibit enhanced catalytic activity and in- creased sensitivity to gefitinib [ J ]. Cancer Res, 2007, 67 (5) : 2325.
  • 9张静,梁智勇,高洁,刘彤华.非小细胞肺癌表皮生长因子受体基因及k-ras基因突变与临床病理特征的关系[J].协和医学杂志,2010,1(1):53-59. 被引量:18
  • 10张恒,徐亮,闵生萍.液基薄层细胞学检测技术在肺癌诊断中的应用[J].中华全科医学,2011,9(8):1296-1297. 被引量:18

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部